These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6155578)

  • 1. Resistance against subcutaneous insulin successfully managed with aprotinin.
    Müller WA; Taillens C; Léreret S; Berger M; Philippe J; Halban PA; Offord RE
    Lancet; 1980 Jun; 1(8180):1245-6. PubMed ID: 6155578
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetes resistant to subcutaneous insulin: effect of aprotinin.
    N Engl J Med; 1981 Dec; 305(23):1413-4. PubMed ID: 6170889
    [No Abstract]   [Full Text] [Related]  

  • 3. Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.
    Williams G; Pickup JC; Bowcock S; Cooke E; Keen H
    Diabetologia; 1983 Feb; 24(2):91-4. PubMed ID: 6188643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin resistance caused by an increase in proteolytic enzyme activity at the site of insulin injection. Study in insulin-dependent diabetic subjects].
    Calle Pascual AL; Marañes Pallardó JP; Charro Salgado AL
    Med Clin (Barc); 1983 Apr; 80(12):524-6. PubMed ID: 6191160
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of aprotinin in insulin resistance caused by subcutaneous degradation of insulin].
    Sudre Y; Marechaud R; Abadie JC; Rossi F; Gouet D
    Nouv Presse Med; 1982 Jan; 11(2):131-2. PubMed ID: 6173842
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects.
    Berger M; Cüppers HJ; Halban PA; Offord RE
    Diabetes; 1980 Jan; 29(1):81-3. PubMed ID: 6155298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous degradation of insulin.
    Stevenson RW
    Diabetologia; 1982 Mar; 22(3):221-3. PubMed ID: 6176491
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose insulin infusions in diabetic patients with high insulin requirements.
    Dandona P; Foster M; Healey F; Greenbury E; Beckett AG
    Lancet; 1978 Aug; 2(8084):283-5. PubMed ID: 79081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient.
    Maberly GF; Wait GA; Kilpatrick JA; Loten EG; Gain KR; Stewart RD; Eastman CJ
    Diabetologia; 1982 Oct; 23(4):333-6. PubMed ID: 6183163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-four hour blood glucose profiles during insulin and insulin plus aprotinin subcutaneous administration in type I diabetes.
    Lunetta M; Napoli E; Sudano L; Leonardi R; Mughini L
    Horm Metab Res; 1986 Mar; 18(3):182-4. PubMed ID: 2422103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin.
    Freidenberg GR; White N; Cataland S; O'Dorisio TM; Sotos JF; Santiago JV
    N Engl J Med; 1981 Aug; 305(7):363-8. PubMed ID: 7019707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprotinin induced lipohypertrophy and glomerulonephritis in an insulin dependent diabetic.
    Dandona P; Mier A; Boag F; Chappell M; Beckett AG
    Diabetes Res; 1985 Jul; 2(4):213-6. PubMed ID: 2417774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous absorption of U-40 and U-100 insulin.
    Lauritzen T; Thorsteinsson B; Pramming S; Sørensen L; Binder C
    Horm Metab Res; 1984 Nov; 16(11):611-2. PubMed ID: 6392055
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous insulin resistance syndrome. Effects of long-term aprotinin therapy.
    Guillausseau PJ; Guillausseau C; Boucheteil P; Lubetzki J
    Diabetes Res; 1986 Sep; 3(7):387-9. PubMed ID: 2430751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous injections and absorption of insulin.
    Lancet; 1980 May; 1(8176):1005-6. PubMed ID: 6103328
    [No Abstract]   [Full Text] [Related]  

  • 16. Neonatal diabetes mellitus: Insulin pump as an alternative management strategy.
    Bharucha T; Brown J; McDonnell C; Gebert R; McDougall P; Cameron F; Werther G; Zacharin M
    J Paediatr Child Health; 2005; 41(9-10):522-6. PubMed ID: 16150072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Respective contributions of the method of insulin injection and its absorption by subcutaneous route in the etiopathogenesis of unstable diabetes].
    Home PD
    Journ Annu Diabetol Hotel Dieu; 1995; ():243-55. PubMed ID: 7602885
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of aprotinin on regional absorption of soluble human insulin.
    Owens DR; Vora JP; Birtwell J; Luzio S; Hayes TM
    Br J Clin Pharmacol; 1988 Apr; 25(4):453-6. PubMed ID: 2454647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coincidence of hepatic angiosarcoma and insulin-resistance diabetes mellitus with high-dose intraperitoneal insulin therapy].
    Kersten A; Schwarzkopf J; Petersen KG; Lohner M
    Verh Dtsch Ges Pathol; 1994; 78():285-7. PubMed ID: 7534000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous-insulin-resistance syndrome.
    N Engl J Med; 1987 Jan; 316(1):49-51. PubMed ID: 3537795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.